Cutia Therapeutics
HKEX:2487
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.7
22.8
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Cutia Therapeutics stock under the Base Case scenario is 16.95 HKD. Compared to the current market price of 14.06 HKD, Cutia Therapeutics is Undervalued by 17%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Cutia Therapeutics
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for Cutia Therapeutics cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Cutia Therapeutics
Balance Sheet Decomposition
Cutia Therapeutics
Current Assets | 1.2B |
Cash & Short-Term Investments | 1B |
Receivables | 54.6m |
Other Current Assets | 116.4m |
Non-Current Assets | 297.7m |
PP&E | 223.4m |
Intangibles | 8.2m |
Other Non-Current Assets | 66.1m |
Current Liabilities | 237.8m |
Accounts Payable | 55.4m |
Other Current Liabilities | 182.4m |
Non-Current Liabilities | 81.7m |
Long-Term Debt | 81.7m |
Earnings Waterfall
Cutia Therapeutics
Revenue
|
198.9m
CNY
|
Cost of Revenue
|
-98.8m
CNY
|
Gross Profit
|
100.1m
CNY
|
Operating Expenses
|
-627m
CNY
|
Operating Income
|
-526.9m
CNY
|
Other Expenses
|
2.6m
CNY
|
Net Income
|
-524.3m
CNY
|
Free Cash Flow Analysis
Cutia Therapeutics
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Cutia Therapeutics's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Score
Cutia Therapeutics's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Cutia Therapeutics's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Score
Cutia Therapeutics's solvency score is 82/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Cutia Therapeutics
According to Wall Street analysts, the average 1-year price target for Cutia Therapeutics is 12.17 HKD with a low forecast of 9.7 HKD and a high forecast of 15.96 HKD.
Shareholder Yield
Current shareholder yield for Cutia Therapeutics is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Price
Cutia Therapeutics
Average Annual Return |
N/A
|
Standard Deviation of Annual Returns |
N/A
|
Max Drawdown | -82% |
Market Capitalization | 4.3B HKD |
Shares Outstanding | 304 024 000 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Cutia Therapeutics is a holding company that engages in the research and development of dermatology treatment solutions and products through its subsidiaries. The company is headquartered in Shanghai, Shanghai and currently employs 175 full-time employees. The company went IPO on 2023-06-12. The firm is committed to developing comprehensive solutions to meet the diverse needs of patients and consumers in a wide range of dermatological treatment and care markets. The firm is mainly engaged in clinical trials of its core product CU-20401. This product is mainly used to treat submental fat accumulation. The firm conducts its businesses in the domestic market and overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one Cutia Therapeutics stock under the Base Case scenario is 16.95 HKD.
Compared to the current market price of 14.06 HKD, Cutia Therapeutics is Undervalued by 17%.